Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.32 |
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1457055 | 0.96 | P2RY14 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL18660233 | 0.85 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL4064959 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL11266879 | 0.83 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL2367603 | 0.80 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL18660220 | 0.80 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL23831167 | 0.79 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL7456552 | 0.79 | SLC28A1 (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL5574929 | 0.79 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL154357 | 0.79 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| US-10273484-B2 | Double-stranded RNA conjugates and their use | RIBOXX GMBH (DE) | 2019-04-30 | — | — | US | claimed |
| US-20170107517-A1 | Double-Stranded RNA Conjugates And Their Use | RIBOXX GMBH (DE) | 2017-04-20 | — | — | US | claimed |
| EP-3126501-A1 | DOUBLE-STRANDED RNA CONJUGATES AND THEIR USE | RiboxX GmbH (DE) | 2017-02-08 | — | — | EP | claimed |
| WO-2015144736-A1 | DOUBLE-STRANDED RNA CONJUGATES AND THEIR USE | RIBOXX GMBH (DE) | 2015-10-01 | — | — | WO | claimed |
| EP-1572902-B1 | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES | LIFE TECHNOLOGIES CORP (US) | 2014-06-11 | — | — | EP | claimed |
| US-20260043089-A1 | COMPOSITIONS AND METHODS FOR DETECTING CIRCULATING TUMOR DNA | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12404556-B2 | Compositions and methods for detecting circulating tumor DNA | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024249967-A1 | RNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-117004721-A | Compositions and methods for detecting circulating tumor DNA | 奎斯特诊断投资有限责任公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-110741096-B | Compositions and methods for detecting circulating tumor DNA | 奎斯特诊断投资有限责任公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230124718-A1 | NOVEL ADAPTOR FOR NUCLEIC ACID SEQUENCING AND METHOD OF USE | Roche Sequencing Solutions, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-7547530-B2 | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof | AMBERGEN, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1415001-A4 | NUCLEOTIDE COMPOSITIONS COMPRISING PHOTOCLEAVABLE MARKERS AND METHODS OF PREPARATION THEREOF | AMBERGEN INC (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060252923-A1 | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof | AMBERGEN, INC. (US) | 2006-11-09 | — | — | US | disclosed |
| US-7057031-B2 | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof | AMBERGEN, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1415001-A2 | NUCLEOTIDE COMPOSITIONS COMPRISING PHOTOCLEAVABLE MARKERS AND METHODS OF PREPARATION THEREOF | Ambergen, Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20030099972-A1 | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof | AMBERGEN, INC. (US) | 2003-05-29 | — | — | US | disclosed |
| WO-2003006625-A2 | NUCLEOTIDE COMPOSITIONS COMPRISING PHOTOCLEAVABLE MARKERS AND METHODS OF PREPARATION THEREOF | AMBERGEN, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252923-A1 | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof | POLN, NT5C3B, RNGTT | SLC28A1 342/4885SLC28A2 341/4885SLC29A1 77/4885 |
| US-20260043089-A1 | COMPOSITIONS AND METHODS FOR DETECTING CIRCULATING TUMOR DNA | DNMT3A, DNMT3L, MCTS1 | SLC28A1 1141/4885SLC28A2 1194/4885SLC29A1 543/4885 |
| US-10273484-B2 | Double-stranded RNA conjugates and their use | ADAR, TRDMT1, EIF2AK2 | SLC28A1 1920/4885SLC28A2 1812/4885SLC29A1 1007/4885 |
| US-20030099972-A1 | Nucleotide compositions comprising photocleavable markers and methods of preparation thereof | POLN, NT5C3B, RNGTT | SLC28A1 342/4885SLC28A2 341/4885SLC29A1 77/4885 |
| US-20170107517-A1 | Double-Stranded RNA Conjugates And Their Use | ADAR, TRDMT1, EIF2AK2 | SLC28A1 1920/4885SLC28A2 1812/4885SLC29A1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.